Company profile: Galapagos
1.1 - Company Overview
Company description
- Provider of small molecule medicines and investigational therapies in immunology and oncology. Develops CAR-T cell therapies via a decentralized manufacturing network and advances GLPG5101 (Phase 1/2 for relapsed/refractory non-Hodgkin lymphoma). Conducts clinical trials to evaluate treatments and seek regulatory approval; Jyseleca (filgotinib) transferred to Alfasigma.
Products and services
- Small Molecule Medicines: Galapagos engineers clinical-stage small molecule medicines with novel modes of action, discovered and developed for various therapeutic areas, with a focus on immunology and oncology
- CAR-T Therapies: Galapagos architects decentralized CAR-T cell therapies for oncology, utilizing a manufacturing network to produce innovative cellular products under development
- GLPG5101: Galapagos produces investigational treatment evaluated in a Phase 1/2 study for relapsed/refractory non-Hodgkin lymphoma, advancing potential therapy for resistant lymphoma patients through defined clinical assessment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Galapagos
Kynos Therapeutics
HQ: United Kingdom
Website
- Description: Provider of small-molecule KMO inhibitor therapeutics for inflammation, immunity, and metabolism. Offers KNS366, a Phase I KMO inhibitor designed to reduce elevated 3-HK to prevent tissue damage and immune dysregulation during inflammation, and a portfolio targeting acute and chronic inflammatory disorders, including acute kidney injury and acute pancreatitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kynos Therapeutics company profile →
Gesynta Pharma
HQ: Sweden
Website
- Description: Provider of clinical-stage pharmaceutical R&D developing mPGES-1–inhibiting drug candidates to reduce inflammation and pain. Pipeline includes vipoglanstat (GS-248), a non-hormonal treatment for endometriosis in phase II, and GS-073 for chronic inflammatory pain entering phase I. Research originates from Karolinska Institutet; GS-073 from AstraZeneca.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gesynta Pharma company profile →
Provention Bio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical solutions dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge approaches to intercept and prevent immune-mediated disease, using a predict-and-prevent model to intervene before disease onset.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Provention Bio company profile →
Triveni Bio
HQ: United States
Website
- Description: Provider of genetically informed functional antibody therapeutics for immunological and inflammatory disorders, supported by a proprietary data platform that leverages public and private datasets to identify therapeutic targets, predict patient subpopulations, and provide disease insights; lead program TRIV-509 targets kallikreins 5 and 7 for atopic dermatitis and other barrier disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Triveni Bio company profile →
ProtaGene
HQ: Germany
Website
- Description: Provider of precision medicine solutions supporting drug development, treatment strategies, and patient management, with expertise in immuno-profiling and discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology, leveraging SeroTag® technology to identify biomarkers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProtaGene company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Galapagos
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Galapagos
2.2 - Growth funds investing in similar companies to Galapagos
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Galapagos
4.2 - Public trading comparable groups for Galapagos
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →